On July 9, Alibaba Health declined 3.16% in regular trading, trading at HK$3.37, with turnover of HK$201 million. The decline was driven by broad selling pressure across the online healthcare sector, combined with profit-taking following the stock's 6.75% surge in the prior session.

On the sector front, peers including JD Health fell 2.41% and Ping An Good Doctor dropped 4.78%, reflecting widespread weakness in the medical e-commerce space that dragged Alibaba Health lower. The sharp rally on the previous trading day, fueled by a share buyback proposal and strong annual results, created conditions for near-term profit-taking as short-term gains were locked in.

Adding to bearish sentiment, UBS recently maintained its Sell rating on Alibaba Health and cut the target price to HK$3.1, while reducing earnings forecasts for fiscal years 2027 to 2029 by 5%. The bank projects revenue and adjusted net profit compound annual growth rates of only 12% and 5% respectively through fiscal 2029, signaling subdued growth expectations that continue to cap upside potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)